drugset / Trial / NCT05705466
Study of Navtemadlin Plus Pembrolizumab as Maintenance Therapy in Locally Advanced and Metastatic Non-Small Cell Lung Cancer
RandomizedParallel-groupQuadruple-blindTreatment
Summary
This study evaluates Navtemadlin (KRT-232) in combination with Pembrolizumab as a maintenance therapy in patients with locally advanced and metastatic non small cell lung cancer.
Timeline
- Start
- 2023-06
- Primary completion
- 2025-06
- Completion
- 2027-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Navtemadlin | Small molecule | — | Oral |
| Background | Pembrolizumab | Monoclonal antibody | — | Intravenous |